Establishing a robust radioligand therapy program: A practical approach for North American centers.

Authors:
Mittra ES; Wong RKS; Winters C; Brown A; Murley S and 1 more

Journal:
Cancer Med

Publication Year: 2024

DOI:
10.1002/cam4.6780

PMCID:
PMC10905220

PMID:
38214130

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Cancer Med

Abbreviation: Cancer Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accessibility to ERCP-performing hospitals among patients with pancreatic cancer living in SEER reg…
Tavakkoli A; Beauchamp A; Prasad T and 7 more (2024) - Transparency Score: 4/6
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
Judd S; Revon-Riviere G; Grover SA and 17 more (2024) - Transparency Score: 3/6
A comprehensive narrative review of challenges and facilitators in the implementation of various HP…
Aggarwal S; Agarwal P; Gupta N. (2024) - Transparency Score: 3/6
A computed tomography urography-based machine learning model for predicting preoperative pathologic…
Zheng Y; Shi H; Fu S and 6 more (2024) - Transparency Score: 3/6
Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequenci…
Zazo S; Pérez-Buira S; Carvajal N and 12 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data s1: supporting information."

Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT Erik S. Mittra reports consulting fees from Amgen, Curium, Novartis, TerSera, and ITM and research funding from Novartis and Nordic Nanovector. Rebecca K.S. Wong reports education grants from Elekta, Celgene, and Bruce Power, a research grant from Ontario Health, and honoraria from Novartis. Hagen Kennecke reports advisory fees from Tersera and Novartis and research funding from Novartis, Exelixis, and Taiho. No other potential conflicts of interest relevant to this article exist."

Evidence found in paper:

"FUNDING INFORMATION Novartis Pharmaceuticals Corporation provided funding for medical writing assistance."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025